Eisai/Biogen Remain In BACE Race As Alzheimer's Contenders Dwindle
Multiple competitors have ended development of BACE inhibitors for the treatment of Alzheimer's disease, but Eisai neurology executive Lynn Kramer tells Scrip that the company still sees a path forward for certain amyloid-targeting drugs.
You may also be interested in...
Biogen and Eisai still have multiple programs testing amyloid-targeting therapies in the treatment of Alzheimer's disease, but pressure for Biogen to focus its efforts elsewhere are mounting after the partners discontinued Phase III studies for aducanumab.
The firm announced plans to begin a Phase III study of aducanumab to prevent or delay the onset of Alzheimer’s, but refused to discuss ongoing studies during its fourth quarter earnings call.
It is a field littered with failures but Eisai remains hopeful that its pipeline of candidates for Alzheimer's disease, which has just been added to, gives the firm a number of shots at getting a disease-modifying agent to market.